At Soulmates Ventures, we invest in founders building breakthrough solutions to the world’s most pressing challenges. One of our latest investments is in Better Medicine, an Estonia-based healthtech startup on a mission to transform cancer diagnostics with artificial intelligence.
Better Medicine has just secured €1 million in pre-seed funding, with Soulmates Ventures leading the round alongside Specialist VC, UT Ventures, and several angel investors. The round follows a €2.5 million grant from the European Innovation Council (EIC) earlier this year, reflecting a strong alignment between public support and private capital. With additional grants and prior investment, the company has now raised €2.25 million in private funding and €3.7 million in total grants, bringing overall funding close to €6 million.
⸻
A critical gap in cancer diagnostics
Radiology departments worldwide face a growing challenge: rising demand for diagnostic imaging and too few trained radiologists. In the UK, there are just 10 radiologists per 100,000 people, and 50% of radiology job postings remain unfilled. Globally, an estimated 12 million hours each year are spent on manual lesion measurements and reporting—time that could be better spent on complex cases requiring human expertise.
This bottleneck contributes to delays, missed diagnoses, and increased burnout in a profession where speed and accuracy can be lifesaving.
⸻
The world’s first CE-certified AI for kidney cancer detection
Better Medicine is tackling this issue with clinically validated AI models that detect, measure, and report oncological findings in CT scans.
Its flagship product, BMVision Kidney, recently became the first CE-certified AI tool for kidney cancer detection under the EU Medical Device Regulation (MDR 2017/745). In clinical use, it has delivered up to 52% time savings and helped radiologists achieve a 99.2% detection rate.
BMVision Kidney uses deep learning models trained on large, annotated clinical datasets to detect malignant kidney lesions with 96% standalone accuracy—and even higher detection rates when paired with a radiologist’s review.
⸻
BM iMeasure: speeding up reporting
Complementing BMVision Kidney, Better Medicine has developed BM iMeasure, a companion tool that enables semi-automated lesion measurements and structured reporting. By streamlining these highly repetitive tasks, BM iMeasure reduces the manual workload for radiologists and integrates seamlessly into existing radiology infrastructure, including PACS and standard viewers.
⸻
Improving outcomes and reducing burnout
As Better Medicine’s founder and CEO Priit Salumaa explains:
Radiologists are under immense pressure to maintain focus on repetitive tasks that don’t necessarily require medical expertise but are still critical for diagnosis. Imagine a second set of eyes—multiplied by 1,000—always alert and never tired. We are making early cancer detection easy and freeing doctors to focus on what truly requires their judgment. The upside is more human lives saved.
The company’s long-term vision is to expand the BMVision platform to cover additional organs and metastatic sites, broadening early cancer detection across oncology.
⸻
Why we invested
For us at Soulmates Ventures, Better Medicine represents the kind of high-impact innovation that can create a triple benefit:
1. Better healthcare outcomes for patients
2. Relief for overburdened health systems
3. Strong commercial potential for investors
As our Investment Director Michal Sikyta puts it:
Better Medicine is addressing a clear and urgent need in oncology diagnostics. By supporting radiologists with reliable AI tools, they are improving patient outcomes while easing pressure on overloaded health systems. We’re excited to back this experienced team as they prepare to make a major impact in modern medicine.
⸻
What’s next
With the new funding, Better Medicine will:
• Roll out BMVision Kidney and BM iMeasure across multiple European countries
• Expand its product portfolio to cover more organs and metastatic sites
• Prepare for FDA clearance and launch U.S. clinical pilots tailored to regulatory requirements
• Engage with health insurance providers, starting in Estonia, to demonstrate cost-benefit outcomes and enable sustainable adoption
• Continue forging new clinical partnerships throughout the EU and U.S.
⸻
About Better Medicine
Better Medicine is a medical AI startup developing CE-certified software tools to support cancer detection and diagnosis in radiology. Its BMVision platform integrates directly into radiologists’ workflows to detect and measure oncological findings, starting with kidney lesions. Founded in 2020 and headquartered in Estonia, Better Medicine operates across six countries and collaborates with hospitals and research institutions in Europe, the UK, South Africa, and the U.S.
